ArticleScientific reports2023
Stenotrophomonas maltophilia pneumonia in critical COVID-19 patients.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Risk factors and outcomes associated with difficult-to-treat resistance inEpidemiology and infection · 2026Article
- Temporal trends, antimicrobial non-susceptibility patterns, and clinical predictors of Stenotrophomonas maltophilia in a tertiary care hospital in Palestine: a 7-year retrospective study.BMC infectious diseases · 2026Observational
- Prevalence ofJournal of clinical microbiology · 2026Article
- Healthcare-associated infections in an intensive care unit: a descriptive study, Mato Grosso state, Brazil, 2018-2021.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2026Article
- The Other Face ofAntibiotics (Basel, Switzerland) · 2026Article
- In-hospital antimicrobial use and multidrug-resistant infections among COVID-19 patients in Northern Malaysia (COVAM): a multicentre study.Journal of pharmaceutical policy and practice · 2026Article
- Risk factors and clinical characteristics for Stenotrophomonas maltophilia infection in an acute care hospital in Japan: a single-center retrospective study.Journal of pharmaceutical health care and sciences · 2025Article
- The COVID-19 pandemic: an underlying factor for increasedFrontiers in microbiology · 2025Review
- Prevalence and Molecular Epidemiology of Intestinal Colonization by Multidrug-Resistant Bacteria among Hematopoietic Stem-Cell Transplantation Recipients: A Bulgarian Single-Center Study.Antibiotics (Basel, Switzerland) · 2024Article
- Atypical Presentation of Stenotrophomonas maltophilia Stomatitis Post COVID-19 in an Immunocompetent Adolescent.Cureus · 2024Article
- Impact of Empirical Antimicrobial Treatment on Patients with Ventilator-Associated Pneumonia Due toAntibiotics (Basel, Switzerland) · 2024Article
- Bactericidal effectors of themBio · 2024Article
- A pan-genomic analysis based multi-epitope vaccine development by targetingIn silico pharmacology · 2024Article
- Stenotrophomonas maltophilia Belonging to Novel Sequence Types ST473 and ST474 in Wild Birds Inhabiting the Brazilian Amazonia.Current microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stenotrophomonas maltophilia, an environmental aerobic non-fermentative Gram-negative bacilli, has gained attention in many nosocomial outbreaks. COVID-19 patients in intensive care unit have extended hospital stay and are severely immunosuppressed. This study aimed to determine the prevalence and risk factors of S. maltophilia pneumonia in critical COVID-19 patients. A total of 123 COVID-19 patients in ICU admitted between March 2020 and March 2021 were identified from the authors' institutional database and assessed for nosocomial pneumonia. Demographic data and factors predisposing to S. maltophilia pneumonia were collected and analyzed. The mean age was 66 ± 13 years and 74% were males. Median APACHE and SOFA scores were 13 (IQR = 8-19) and 4 (3-6), respectively. The Median NEWS2 score was 6 (Q1 = 5; Q3 = 8). The Median ICU stay was 12 (Q1 = 7; Q3 = 22) days. S. maltophilia was found in 16.3% of pneumonia patients, leading to a lengthier hospital stay (34 vs. 20 days; p < 0.001). Risk factors for S. maltophilia pneumonia included previous treatment with meropenem (p < 0.01), thrombopenia (p = 0.034), endotracheal intubation (p < 0.001), foley catheter (p = 0.009) and central venous catheter insertion (p = 0.016). S. maltophilia nosocomial pneumonia is frequent in critical COVID-19 patients. Many significant risk factors should be addressed to reduce its prevalence and negative impact on outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.